BHC(SH:600721) Xin Lang Cai Jing·2025-09-16 02:48Company Overview - Xinjiang Baihua Village Pharmaceutical Group Co., Ltd. is located in Urumqi, Xinjiang, and was established on June 21, 1996, with its listing date on June 26, 1996 [2] - The company specializes in early drug discovery and screening, drug CMC development, clinical trials, registration applications, bio-sample analysis, and pharmaceutical testing services, providing a comprehensive outsourcing and technology transfer service [2] - The main business revenue composition includes: clinical trials 49.39%, pharmaceutical R&D and consistency evaluation 42.67%, leasing and property services 6.69%, and other income 0.94% [2] Financial Performance - For the first half of 2025, the company achieved operating revenue of 202 million yuan, a year-on-year increase of 2.95%, and a net profit attributable to the parent company of 25.48 million yuan, a year-on-year increase of 12.45% [2] - As of June 30, the number of shareholders was 30,000, a decrease of 26.42% from the previous period, while the average circulating shares per person increased by 35.95% to 12,799 shares [2] Stock Performance - On September 16, the stock price of Baihua Pharmaceutical fell by 2.07% to 9.92 yuan per share, with a trading volume of 76.24 million yuan and a turnover rate of 1.98%, resulting in a total market capitalization of 3.815 billion yuan [1] - Year-to-date, the stock price has increased by 50.53%, with a recent decline of 2.27% over the last five trading days, a 13.24% increase over the last 20 days, and a 36.26% increase over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on September 4, where it recorded a net buy of -57.5752 million yuan [1] Dividend Information - Since its A-share listing, the company has distributed a total of 6.1275 million yuan in dividends, with no dividends paid in the last three years [3]